In oncology, an emerging paradigm emphasises molecularly targeted approaches for cancer prevention and therapy and the use of adjuvant chemotherapeutics to overcome cisplatin limitations. Owing to their safe use, some polyphenols, such as curcumin, modulate important pathways or molecular targets in cancers. This paper focuses on curcumin as an adjuvant molecule to cisplatin by analysing its potential implications on the molecular targets, signal transducer and activator of transcription 3 (STAT3) and NF-E2 p45-related factor 2 (Nrf-2), in tumour progression and cisplatin resistance in vitro and the adverse effect ototoxicity in vivo.

Molecular targets for anticancer redox chemotherapy and cisplatin-induced ototoxicity: the role of curcumin on pSTAT3 and Nrf-2 signalling / Fetoni, A.R., Paciello, F., Mezzogori, D., Rolesi, R., Eramo, S.L.M., Paludetti, G., Troiani, D.. - In: BRITISH JOURNAL OF CANCER. - ISSN 1532-1827. - 113:10(2015), pp. 1434-1444. [10.1038/bjc.2015.359]

Molecular targets for anticancer redox chemotherapy and cisplatin-induced ototoxicity: the role of curcumin on pSTAT3 and Nrf-2 signalling

Fetoni, Anna Rita;
2015

Abstract

In oncology, an emerging paradigm emphasises molecularly targeted approaches for cancer prevention and therapy and the use of adjuvant chemotherapeutics to overcome cisplatin limitations. Owing to their safe use, some polyphenols, such as curcumin, modulate important pathways or molecular targets in cancers. This paper focuses on curcumin as an adjuvant molecule to cisplatin by analysing its potential implications on the molecular targets, signal transducer and activator of transcription 3 (STAT3) and NF-E2 p45-related factor 2 (Nrf-2), in tumour progression and cisplatin resistance in vitro and the adverse effect ototoxicity in vivo.
2015
Molecular targets for anticancer redox chemotherapy and cisplatin-induced ototoxicity: the role of curcumin on pSTAT3 and Nrf-2 signalling / Fetoni, A.R., Paciello, F., Mezzogori, D., Rolesi, R., Eramo, S.L.M., Paludetti, G., Troiani, D.. - In: BRITISH JOURNAL OF CANCER. - ISSN 1532-1827. - 113:10(2015), pp. 1434-1444. [10.1038/bjc.2015.359]
File in questo prodotto:
File Dimensione Formato  
Fetoni et al., 2015 BJC.pdf

non disponibili

Dimensione 3.04 MB
Formato Adobe PDF
3.04 MB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11588/871846
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 114
  • ???jsp.display-item.citation.isi??? 100
social impact